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Introduction
■  Neratinib, an irreversible tyrosine kinase inhibitor of HER1, HER2 and HER4,1  
is used for the extended adjuvant treatment of early-stage HER2-positive 
(HER2+) breast cancer after trastuzumab-based adjuvant therapy.
‒  The primary analysis of the international, randomized, placebo-controlled 
phase III ExteNET trial showed that 1 year of neratinib given after trastuzumab-
based (neo)adjuvant therapy significantly improved 2-year invasive disease-free 
survival (iDFS) compared with placebo in women with early-stage HER2-
positive breast cancer (stratified hazard ratio [HR] 0.67; 95% confidence 
intervals [CI] 0.50–0.91; p=0.0091).2
‒  Furthermore, the significant iDFS benefits of neratinib were maintained after  
a median of 5 years’ follow-up (stratified hazard ratio 0.73; 95% CI 0.57‒0.92; 
p=0.008).3
■  Current knowledge about breast cancer is based largely on studies conducted in 
western populations.4 
–  As the genetic background, socio-economic profile, lifestyle, and health beliefs 
of Asian and western women differ, the findings from such studies may not be 
applicable to Asian women.4
‒  We report exploratory analyses from the ExteNET trial of patients enrolled 
from Asian centers to better understand the efficacy and safety of neratinib 




■  ExteNET is a multicenter, randomized, double-blind, parallel, placebo-controlled, 
phase III trial.
■  Patients were enrolled from centers in 40 countries in Europe, North and South 
America, Asia, and Australasia. 
■  The final study design comprised 3 parts: 
–  Part A: primary efficacy analysis at 2 years (July 2014)2
‒ Part B: sensitivity analysis of efficacy at 5 years (March 2017)3
‒ Part C: analysis of overall survival which is planned after 248 events. 
■  ExteNET is registered on Clinicaltrials.gov (identifier, NCT00878709).
Patients
■  Women with confirmed stage 2–3c (1–3c in original protocol) HER2-positive 
breast cancer.
■  Clinical and radiologic assessments were required to be negative for recurrences 
or metastatic disease at study entry.
■  Patients had received (neo)adjuvant therapy with trastuzumab completed within 
1 year (2 years in original protocol) before randomization.
Treatment
■  Women were randomly assigned to oral neratinib 240 mg once daily continuously 
or matching placebo for 1 year. 
■  Prophylaxis for the prevention of neratinib-associated diarrhea was not mandatory.
Assessments
■  During years 1 and 2, physical examinations were performed at month 1, every 
3 months during year 1, and every 4 months during year 2, mammograms were 
performed annually where appropriate, and computed tomography or bone 
scans were performed if clinically indicated. 
■  During years 3 to 5, physical examination and mammogram schedules were 
based on standard of care, and details of recurrent disease events and deaths 
were obtained from medical records.
Outcomes
■  The primary study endpoint was iDFS after 2 years of follow-up.
■  Secondary endpoints included disease-free survival including ductal carcinoma 
in situ (DCIS), time to distant recurrence, distant disease-free survival, cumulative 
incidence of central nervous system (CNS) recurrences, and safety.
Statistical analysis
■  Exploratory analyses were performed in the subpopulation of patients enrolled 
from Asian countries (i.e. China, Hong Kong, Japan, Korea, Malaysia, Singapore, 
and Taiwan).
■  Patients of Asian ethnicity enrolled from non-Asian countries (n=44) were not 
included in the Asian subpopulation. 
■  Efficacy analyses were by intention-to-treat and performed at 2 and 5 years 
post-randomization.
■  Kaplan Meier methods were used to analyze time-to-event endpoints, and a 
unstratified Cox proportional-hazards model was used to estimate HR with 95% 
CI for neratinib versus placebo.
Results
■  2840 women were randomly assigned to study treatment and constituted the 
intention to-treat population (neratinib, n=1420; placebo, n=1420).
■  341 women were enrolled from centers in Asia (neratinib, n=165; placebo, 
n=176) [Figure 1].
Figure 1. ExteNET analysis flowchart 
■  Patient demographics and characteristics at baseline were generally balanced 
between treatment groups in the Asian population (Table 1).
■  Compared with the intention-to-treat population, Asian patients (neratinib and 
placebo combined) were more likely to have node-negative disease (28.7% vs 
23.6%) and hormone receptor-negative tumors (52.2% vs 42.6%). 
■  Asian patients were also less likely to have received trastuzumab concurrently 
with chemotherapy (41.3% vs 62.3% in the intention-to-treat population),  
but more likely to have received an anthracycline plus taxane (81.2% vs 67.9%). 













Age, years, median (range) 52 (26–81) 53 (27–72) 52 (25–83) 52 (23–82)
Body mass index, kg/m2 mean (SD) 22.6 (3.8) 23.1 (3.3) 27.4 (5.8) 27.5 (5.8)
Nodal status*
Negative 









































































Data are presented as n (%), unless otherwise stated. SD, standard deviation. 
*Stratification factor.
Efficacy
■  Efficacy findings are summarized in Table 2 and Kaplan-Meier curves for iDFS 
are presented in Figure 2.
■  After 2 years’ follow-up, the iDFS rate in the Asian population was 92.8% in the 
neratinib group and 90.8% in the placebo group (HR 0.71; 95% CI 0.31–1.57), 
corresponding with an absolute between-group difference of 2.0%.
■  For other secondary endpoints, the trend favoring neratinib treatment was also 
consistently observed (Table 2). 
■  After 5 years’ follow-up, the iDFS rate in the Asian population was 91.9% in the 
neratinib group and 87.2% in the placebo group (HR 0.54; 95% CI 0.26–1.08), 
corresponding with an absolute between-group difference of 4.7%.
■  The number of CNS recurrences was numerically smaller in the neratinib group 
than in the placebo group at both time-points (1 vs 4 events, respectively).
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CNS, central nervous system; CI, confidence intervals; DCIS, ductal carcinoma in situ.
Figure 2. iDFS in Asian and intention-to-treat populations at 2 years (A) and  
5 years (B) 
Treatment exposure
■  In the Asian population, the median duration of treatment was similar in both 
treatment arms (neratinib, 11.5 months; placebo, 11.6 months).
■  However, Asian patients were more likely to complete study treatment (neratinib, 
70.3%; placebo, 85.8%) than patients in the overall study population (62.1% vs 
82.9%, respectively).
Safety
■  In the Asian population, diarrhea was the most common adverse event with 
neratinib (Table 3); no grade 4 diarrhea occurred in either treatment group.
■  All other grade 3 events occurred in single patients only with neratinib.
■  Grade 4 events were reported in 1 patient (0.6%) in the neratinib group (anemia) 
and 3 patients (1.7%) in the placebo group (brain edema, n=1; amylase 
increased, abnormal hepatic function, cholestatic jaundice, n=1; gastric cancer, 
n=1). No grade 4 event was considered to be treatment related.
■  One grade 5 event (gastric cancer) occurred in the placebo group.




























































































Note: Adverse events were graded according to National Cancer Institute Common Terminology 
Criteria, version 3.0.
■  With the exception of lower rates of dizziness and nasopharyngitis, Asian 
patients treated with neratinib experienced higher rates of all-grade adverse 
events compared with those who received placebo.
■  Grade 3 diarrhea was also more common with neratinib in Asian patients (46.1%) 
compared with the rate seen in the overall safety population (39.8%).
Conclusions
■  In ExteNET, the benefits of neratinib appeared to be similar among 
Asian patients than in the intention-to-treat population at both the 
2-year and 5-year timepoints.
■  Asian patients treated with neratinib experienced a higher rate 
of most adverse events compared with those receiving placebo, 
although this did not appear to impact on treatment duration or 
efficacy outcome. 
■  Despite small patient numbers, our analyses suggest that the 
findings from ExteNET are applicable to Asian patients.
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